Texas makes its mark on psychedelics sector with US$50M in ibogaine research funding

Texas makes its mark on psychedelics sector with US$50M in ibogaine research funding

Texas is making history by funding a major ibogaine research initiative with an unprecedented sum. As the United States continues to grapple with an increasing rate of mental health conditions, the need for efficacious new treatment modalities is immense.

This is particularly true among the American veterans community. Depression, PTSD, and substance use disorders resulting from those conditions are alarmingly prevalent. So is suicide, unfortunately.

On Thursday, a press release credited to the Texas ...

Continue Reading →

Results of the Long-Term Outcomes Study of Ibogaine Treatment in Mexico – Thomas Kingsley Brown



http://psychedelicscience.org

Help us caption and translate this video on Amara.org:‪ ‬http://www.amara.org/en/videos/ypBoaytF37qb/info/

Results of the Long-Term Outcomes Study of Ibogaine Treatment in Mexico

Thomas Kingsley Brown, PhD

This presentation is an overview of the MAPS-funded study of long-term outcomes for ibogaine-assisted treatment of opiate dependence for patients at two clinics in Baja California, Mexico. Beginning in September of 2010, the study enrolled thirty US residents seeking ibogaine treatment for opiate dependence at the ...

Continue Reading →

Notes on Progress in the New Zealand Ibogaine Study – Geoff Noller



http://psychedelicscience.org

Help us caption and translate this video on Amara.org:‪ ‬http://www.amara.org/en/videos/w5HzSJBjBSdf/info/

Notes on Progress in the New Zealand Ibogaine Study

Geoff Noller, PhD

This presentation reports on the first year of progress in the New Zealand observational study of ibogaine treatment outcomes for opioid-dependent persons. Current participants’ data are reviewed and the implications of New Zealand’s ibogaine legislation for research and treatment are discussed.

Dr. Geoff Noller has a background in social ...

Continue Reading →
UA-77446339-1